A Multi-Center, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Proof of Concept, Adaptive, Phase 1b Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
Latest Information Update: 10 Jun 2024
At a glance
- Drugs TERN 201 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept
- Acronyms AVIATION
- Sponsors Terns Pharmaceuticals
Most Recent Events
- 24 Jun 2023 Results of pooled analysis from LIFT and AVIATION presented at the European Association for the Study of the Liver Congress 2023
- 29 Sep 2022 Status changed from active, no longer recruiting to completed.
- 26 Jun 2022 Interim results (n=30) from Part 1 of Phase 1b portion of this trial in patients with NASH presented at The International Liver Congress 2022